139 related articles for article (PubMed ID: 38018812)
21. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
22. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
23. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
[TBL] [Abstract][Full Text] [Related]
24. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.
Harada Y; Kakimoto S; Shimizu T
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32641305
[TBL] [Abstract][Full Text] [Related]
25. Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.
van Kalleveen MW; Walraven M; Hendriks MP
Invest New Drugs; 2018 Jun; 36(3):513-516. PubMed ID: 29464464
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
[TBL] [Abstract][Full Text] [Related]
27. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
Zhong YY; McLean L; Buckle A; Siva S; Tran B
Can J Urol; 2020 Aug; 27(4):10339-10341. PubMed ID: 32861263
[TBL] [Abstract][Full Text] [Related]
28. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
29. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Demircan NC; Alan Ö; Başoğlu Tüylü T; Akın Telli T; Arıkan R; Çiçek FC; Ercelep Ö; Öztürk MA; Alsan Çetin İ; Ergelen R; Tinay İ; Akgül Babacan N; Kaya S; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jul; 26(5):1147-1155. PubMed ID: 31793376
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
31. Pazopanib-induced chylothorax in a patient with renal cell carcinoma.
Koylu B; Tekin F; Aktas BY; Kilickap S; Koksal D
Anticancer Drugs; 2022 Jan; 33(1):e555-e557. PubMed ID: 34387587
[TBL] [Abstract][Full Text] [Related]
32. Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report.
Kuruc Poje D; Božina N; Šimičević L; Žabić I
J Clin Pharm Ther; 2020 Aug; 45(4):628-631. PubMed ID: 32369219
[TBL] [Abstract][Full Text] [Related]
33. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
[TBL] [Abstract][Full Text] [Related]
34. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
[TBL] [Abstract][Full Text] [Related]
35. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
Nhola LF; Abdelmoneim SS; Villarraga HR; Kohli M; Grothey A; Bordun KA; Cheung M; Best R; Cheung D; Huang R; Barros-Gomes S; Pitz M; Singal PK; Jassal DS; Mulvagh SL
J Am Soc Echocardiogr; 2019 Feb; 32(2):267-276. PubMed ID: 30459123
[TBL] [Abstract][Full Text] [Related]
36. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Jeon SY; Lee NR; Yim CY
BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
[TBL] [Abstract][Full Text] [Related]
37. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
38. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
39. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature.
Stein J; Milhem M; Vaena D
J Oncol Pharm Pract; 2020 Jan; 26(1):232-235. PubMed ID: 30961437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
